Jiangsu Hengrui Medicine's high P/E ratio is backed by its p...
Jiangsu Hengrui Medicine's high P/E ratio is backed by its promising earnings outlook. Investors retain the stock, expecting a bright future. The risk of earnings decline is not seen as substantial enough to justify a lower P/E ratio, bolstering the share price.
Jiangsu Hengrui Medicine Co., Ltd.'s (SHSE:600276) Earnings Haven't Escaped The Attention Of Investors
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment